{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:44:36Z","timestamp":1790109876992,"version":"4.0.1"},"reference-count":28,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This article has a companion Counterpoint by Kumar.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018021220","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T11:52:28Z","timestamp":1542109948000},"page":"3045-3049","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Timing of treatment of smoldering myeloma: early treatment"],"prefix":"10.1182","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"first","affiliation":[{"name":"Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-6707","authenticated-orcid":false,"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[{"name":"Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"issue":"25","key":"2020021108385144000_B1","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2020021108385144000_B2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I: a randomized study","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"issue":"7","key":"2020021108385144000_B3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"issue":"10","key":"2020021108385144000_B4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ajh.21821","article-title":"Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma","volume":"85","author":"Detweiler-Short","year":"2010","journal-title":"Am J Hematol"},{"issue":"8","key":"2020021108385144000_B5","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2020021108385144000_B6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect","volume":"118","author":"Mart\u00edn","year":"2002","journal-title":"Br J Haematol"},{"issue":"1","key":"2020021108385144000_B7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2020021108385144000_B8","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"2020021108385144000_B9","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020021108385144000_B10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/leu.2014.313","article-title":"Classifying ultra-high risk smoldering myeloma","volume":"29","author":"Waxman","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2020021108385144000_B11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ejh.12728","article-title":"Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study","volume":"97","author":"S\u00f8rrig","year":"2016","journal-title":"Eur J Haematol"},{"issue":"6","key":"2020021108385144000_B12","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fern\u00e1ndez de Larrea","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2020021108385144000_B13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"34","key":"2020021108385144000_B14","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020021108385144000_B15","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2020021108385144000_B16","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J"},{"issue":"5","key":"2020021108385144000_B17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"18","key":"2020021108385144000_B18","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMc1310911","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","author":"Kristinsson","year":"2013","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2020021108385144000_B19","first-page":"402","article-title":"Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd [abstract]","volume":"130","author":"Mateos","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2020021108385144000_B20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"21","key":"2020021108385144000_B21","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1182\/blood.V122.21.3174.3174","article-title":"Phase II trial of initial safety and toxicity prior to the phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma (E3A06): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]","volume":"122","author":"Lonial","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2020021108385144000_B22","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"22","key":"2020021108385144000_B23","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1182\/blood.V128.22.976.976","article-title":"Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma [abstract]","volume":"128","author":"Ghobrial","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2020021108385144000_B24","first-page":"3155","article-title":"A phase 2, randomized, double-blind, placebo-controlled, multicenter study of siltuximab (anti IL-6 monoclonal antibody) in patients with high-risk smoldering multiple myeloma [abstract]","volume":"130","author":"Brighton","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2020021108385144000_B25","first-page":"510","article-title":"Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study [abstract]","volume":"130","author":"Hofmeister","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2020021108385144000_B26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15384","article-title":"Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study","volume":"182","author":"Jagannath","year":"2018","journal-title":"Br J Haematol"},{"issue":"15 suppl","key":"2020021108385144000_B27","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2018.36.15_suppl.8013","article-title":"Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO) [abstract]","volume":"36","author":"Chari","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020021108385144000_B28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/21\/3045\/1629702\/advances021220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/21\/3045\/1629702\/advances021220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:11:34Z","timestamp":1581412294000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/21\/3045\/16160\/Timing-of-treatment-of-smoldering-myeloma-early"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":28,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018,11,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018021220","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]}}}